Menu
Back to Journals » Drug Design, Development and Therapy » Volume 4
Safety and efficacy of azacitidine in myelodysplastic syndromes
Authors Vigil C, Martin-Santos T, Garcia-Manero G
Published 9 September 2010 Volume 2010:4 Pages 221—229
DOI https://doi.org/10.2147/DDDT.S3143
Review by Single anonymous peer review
Peer reviewer comments 2
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.
Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed.
Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
Keywords: Azacitidine, MDS, hypomethylating agents
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.